News | January 10, 2007

AngioSculpt Now Aimed at Stenosis

Jan. 11, 2007 — AngioScore’s flagship product, the AngioSculpt Scoring Balloon Catheter, has received FDA Premarket Approval (PMA) for use in the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.

With the PMA approval, AngioScore can begin marketing the AngioSculpt in the U.S. for the treatment (as indicated) of coronary artery disease (CAD). The company says that more than one million coronary angioplasty procedures are performed every year in this country, and another 1.5 million procedures are performed worldwide.

AngioSculpt was 510(k) approved in 2005 for balloon dilatation of lesions in infra-popliteal arteries, a key segment of the rapidly growing peripheral artery disease (PAD) market. In addition, the company has also been granted the CE Mark for the AngioSculpt allowing the product to be sold in Europe and the Middle East.

Martin B. Leon, M.D., professor of Medicine at Columbia University and chairman of the Cardiovascular Research Foundation (CRF), served as the principal investigator for the device’s U.S. multicenter clinical trial, a prospective study that evaluated the safety and effectiveness of the AngioSculpt in 200 patients with single or multiple vessel coronary artery disease, in both de novo lesions and in-stent restenosis lesions.

“We are very pleased to have had the opportunity to provide a leadership role in the U.S. clinical trial of the AngioSculpt,” said Dr. Leon. “The results of the clinical trial indicate that the AngioSculpt is a promising new addition for the treatment of coronary artery disease, particularly for challenging lesions and in facilitating precise stent placement and expansion.”

For more information visit

Related Content

Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters| March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Artery Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Sponsored Content | Videos | Guidewires| November 18, 2016
A discussion with guidewire expert Dimitri Karmpaliotis, M.D., Ph.D., FACC, about the basics of interventional guidew
Merit Medical Systems, SwiftNINJA Steerable Microcatheter, FDA 510(k) clearance
Technology | Catheters| November 09, 2016
November 9, 2016 — Merit Medical Systems Inc.
recall, alligator retrieval device, X-Celerator hydrophilic guidewire, UltraFlow flow directed micro catheters, Marathon flow directed micro catheters
News | Cath Lab| October 18, 2016
Medtronic plc announced last week that it has notified customers of a voluntary recall of certain lots of its Pipeline...
Terumo Finecross guidewire illustrates some of the basics of guide wire technology

An illustration of Terumo's Finecross guidewire crossing a tight lesion. 

Feature | Guidewires| October 12, 2016 | Dave Fornell
While guidewires are a key tool used by
Overlay Init